id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-355356-g7lvb8b4	Lamb, Yvette N.	Remdesivir: First Approval	2020-09-01		.txt	text/plain	5025	235	44	Having demonstrated potent antiviral activity against coronaviruses in preclinical studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the current global pandemic. Based on preliminary results from the randomized, double-blind, placebo-controlled, multinational phase III ACTT-1 trial (NCT04280705) in patients with COVID-19, remdesivir significantly reduced time to recovery relative to placebo (median 11 days vs 15 days; rate ratio for recovery 1.32; 95% CI 1.12-1.55; p < 0.001) [primary endpoint] [41] . Among pregnant women (n = 67) and postpartum women (n = 19) who received compassionate use remdesivir for severe COVID-19, rates of clinical improvement were 96% and 89%, respectively, at day 28 [45] . In paediatric patients (aged 0-17 years) with severe COVID-19 treated with compassionate use remdesivir (n = 77), the clinical improvement rate was 88% at day 28 [46] .	./cache/cord-355356-g7lvb8b4.txt	./txt/cord-355356-g7lvb8b4.txt